Human RCTPubMed ID: 33639481·2021

COVID-19 immunotherapy: thymosin alpha-1 efficacy in severe disease

Younes A, Makris A, Hütter G, et al.

Cytokine, 2021 · n = 152

Key finding

Thymosin alpha-1 reduced time on ventilator (8.2 vs 12.4 days); faster CD4+ recovery (150 cells/μL gain vs 31 cells/μL controls).

Summary

RCT of thymosin alpha-1 in hospitalized COVID-19 patients with severe pneumonia, measuring immune recovery and mechanical ventilation duration.

Read the study

The full citation, abstract, and (when available) the full text can be accessed on PubMed. PeptideMark summaries are condensed overviews — we encourage researchers to read primary sources.

View on PubMed

Related compound

Thymosin Alpha-1L4

A naturally occurring thymic peptide approved internationally for immune modulation, with extensive clinical data in hepatitis and cancer immunotherapy.

More research on Thymosin Alpha-1

Combination immunotherapy: thymosin alpha-1 with checkpoint inhibitors in cancer

Journal for ImmunoTherapy of Cancer · 2020 · Human Pilot

Thymalfasin: clinical pharmacology and antiviral applications

BioDrugs · 2010 · Review

Thymosin alpha-1 safety profile: adverse events across 50+ clinical trials

Current Aging Science · 2010 · Review

Thymosin alpha-1 and thymic regeneration in aging

Nature Immunology · 2009 · Animal Study

TNF-α and IL-2 modulation by thymosin alpha-1 in immune cells

Molecular Immunology · 2005 · In Vitro